These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 14968938)

  • 1. Potent and selective inhibition of HIV and SIV by prostratin interacting with viral entry.
    Witvrouw M; Pannecouque C; Fikkert V; Hantson A; Van Remoortel B; Hezareh M; De Clercq E; Brown SJ
    Antivir Chem Chemother; 2003 Nov; 14(6):321-8. PubMed ID: 14968938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.
    Witvrouw M; Pannecouque C; Switzer WM; Folks TM; De Clercq E; Heneine W
    Antivir Ther; 2004 Feb; 9(1):57-65. PubMed ID: 15040537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. env chimeric virus technology for evaluating human immunodeficiency virus susceptibility to entry inhibitors.
    Fikkert V; Cherepanov P; Van Laethem K; Hantson A; Van Remoortel B; Pannecouque C; De Clercq E; Debyser Z; Vandamme AM; Witvrouw M
    Antimicrob Agents Chemother; 2002 Dec; 46(12):3954-62. PubMed ID: 12435701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle.
    Witvrouw M; Fikkert V; Pluymers W; Matthews B; Mardel K; Schols D; Raff J; Debyser Z; De Clercq E; Holan G; Pannecouque C
    Mol Pharmacol; 2000 Nov; 58(5):1100-8. PubMed ID: 11040059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters.
    Pluymers W; Neamati N; Pannecouque C; Fikkert V; Marchand C; Burke TR; Pommier Y; Schols D; De Clercq E; Debyser Z; Witvrouw M
    Mol Pharmacol; 2000 Sep; 58(3):641-8. PubMed ID: 10953059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antireplicative and anticytopathic activities of prostratin, a non-tumor-promoting phorbol ester, against human immunodeficiency virus (HIV).
    Gulakowski RJ; McMahon JB; Buckheit RW; Gustafson KR; Boyd MR
    Antiviral Res; 1997 Jan; 33(2):87-97. PubMed ID: 9021050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A.
    Witvrouw M; Fikkert V; Hantson A; Pannecouque C; O'keefe BR; McMahon J; Stamatatos L; de Clercq E; Bolmstedt A
    J Virol; 2005 Jun; 79(12):7777-84. PubMed ID: 15919930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New anti-HIV agents and targets.
    De Clercq E
    Med Res Rev; 2002 Nov; 22(6):531-65. PubMed ID: 12369088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in both env and gag genes are required for HIV-1 resistance to the polysulfonic dendrimer SPL2923, as corroborated by chimeric virus technology.
    Hantson A; Fikkert V; Van Remoortel B; Pannecouque C; Cherepanov P; Matthews B; Holan G; De Clercq E; Vandamme AM; Debyser Z; Witvrouw M
    Antivir Chem Chemother; 2005; 16(4):253-66. PubMed ID: 16130523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostratin induces HIV activation and downregulates HIV receptors in peripheral blood lymphocytes.
    Rullas J; Bermejo M; García-Pérez J; Beltán M; González N; Hezareh M; Brown SJ; Alcamí J
    Antivir Ther; 2004 Aug; 9(4):545-54. PubMed ID: 15456086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissue.
    Biancotto A; Grivel JC; Gondois-Rey F; Bettendroffer L; Vigne R; Brown S; Margolis LB; Hirsch I
    J Virol; 2004 Oct; 78(19):10507-15. PubMed ID: 15367617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4.
    Schols D; Esté JA; Henson G; De Clercq E
    Antiviral Res; 1997 Aug; 35(3):147-56. PubMed ID: 9298754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
    Koh Y; Das D; Leschenko S; Nakata H; Ogata-Aoki H; Amano M; Nakayama M; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2009 Mar; 53(3):997-1006. PubMed ID: 18955518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.
    Hombrouck A; Van Remoortel B; Michiels M; Noppe W; Christ F; Eneroth A; Sahlberg BL; Benkestock K; Vrang L; Johansson NG; Barreca ML; De Luca L; Ferro S; Chimirri A; Debyser Z; Witvrouw M
    Antimicrob Agents Chemother; 2008 Aug; 52(8):2861-9. PubMed ID: 18541726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
    Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
    J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conserved molecular signatures in gp120 are associated with the genetic bottleneck during simian immunodeficiency virus (SIV), SIV-human immunodeficiency virus (SHIV), and HIV type 1 (HIV-1) transmission.
    Gonzalez MW; DeVico AL; Lewis GK; Spouge JL
    J Virol; 2015 Apr; 89(7):3619-29. PubMed ID: 25589663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A simian-human immunodeficiency virus carrying the rt gene from Chinese CRF01_AE strain of HIV is sensitive to nucleoside reverse transcriptase inhibitors and has a highly genetic stability in vivo.
    Wang W; Yao N; Ju B; Dong Z; Cong Z; Jiang H; Qin C; Wei Q
    Microbes Infect; 2014 Jun; 16(6):461-71. PubMed ID: 24709063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostratin as a new therapeutic agent targeting HIV viral reservoirs.
    Hezareh M
    Drug News Perspect; 2005 Oct; 18(8):496-500. PubMed ID: 16391719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of prostratin on Cyclin T1/P-TEFb function and the gene expression profile in primary resting CD4+ T cells.
    Sung TL; Rice AP
    Retrovirology; 2006 Oct; 3():66. PubMed ID: 17014716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
    Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.